# Maravai Lifesciences Holdings, Inc.: overview

MRVI · Nasdaq · CIK 1823239 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mrvi.md) · [Financials](/companies/mrvi/financials.md) · [Filings](/companies/mrvi/filings.md) · [Insiders](/companies/mrvi/insiders.md)

Latest reported revenue: [$51.4m](/filings/0001823239-26-000059.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001823239-26-000059).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [69.0](/filings/0001823239-25-000120.md) | [56.6 d](/filings/0001823239-26-000011.md) | [46.9](/filings/0001823239-26-000024.md) | [47.4](/filings/0001823239-26-000059.md) | [41.6](/filings/0001823239-25-000120.md) | [49.9 d](/filings/0001823239-26-000011.md) | [65.8](/filings/0001823239-26-000024.md) | [51.4](/filings/0001823239-26-000059.md) |
| Gross margin | % | [46.7%](/filings/0001823239-25-000120.md) | [34.3% d](/filings/0001823239-26-000011.md) | [16.5%](/filings/0001823239-26-000024.md) | [16.4%](/filings/0001823239-26-000059.md) | [13.6%](/filings/0001823239-25-000120.md) | [25.8% d](/filings/0001823239-26-000011.md) | [51.2%](/filings/0001823239-26-000024.md) | [40.1%](/filings/0001823239-26-000059.md) |
| Operating margin | % | [(239.9%)](/filings/0001823239-25-000120.md) | [(66.7%) d](/filings/0001823239-26-000011.md) | [(104.9%)](/filings/0001823239-26-000024.md) | [(139.8%)](/filings/0001823239-26-000059.md) | [(98.6%)](/filings/0001823239-25-000120.md) | [(117.9%) d](/filings/0001823239-26-000011.md) | [(3.3%)](/filings/0001823239-26-000024.md) | [(29.3%)](/filings/0001823239-26-000059.md) |
| Net margin | % | [(140.6%)](/filings/0001823239-25-000120.md) | [(45.8%) d](/filings/0001823239-26-000011.md) | [(63.9%)](/filings/0001823239-26-000024.md) | [(83.5%)](/filings/0001823239-26-000059.md) | [(61.4%)](/filings/0001823239-25-000120.md) | [(71.6%) d](/filings/0001823239-26-000011.md) | [(5.7%)](/filings/0001823239-26-000024.md) | [(24.1%)](/filings/0001823239-26-000059.md) |
| Diluted EPS | $ per share | [(0.68)](/filings/0001823239-25-000120.md) | not reported | [(0.21)](/filings/0001823239-26-000024.md) | [(0.27)](/filings/0001823239-26-000059.md) | [(0.18)](/filings/0001823239-25-000120.md) | not reported | [(0.02)](/filings/0001823239-26-000024.md) | [(0.08)](/filings/0001823239-26-000059.md) |
| Free cash flow | $m | [4.5 d](/filings/0001823239-25-000120.md) | [(20.5) d](/filings/0001823239-26-000011.md) | [(13.9)](/filings/0001823239-26-000024.md) | [(13.1) d](/filings/0001823239-26-000059.md) | [(18.8) d](/filings/0001823239-25-000120.md) | [(24.9) d](/filings/0001823239-26-000011.md) | [4.2](/filings/0001823239-26-000024.md) | [3.6 d](/filings/0001823239-26-000059.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [799](/filings/0001823239-24-000032.md) | [883](/filings/0001823239-25-000034.md) | [289](/filings/0001823239-26-000011.md) | [259](/filings/0001823239-26-000011.md) | [186](/filings/0001823239-26-000011.md) |
| Gross margin | % | not reported | not reported | [48.5%](/filings/0001823239-26-000011.md) | [41.8%](/filings/0001823239-26-000011.md) | [18.3%](/filings/0001823239-26-000011.md) |
| Operating margin | % | [69.4%](/filings/0001823239-24-000032.md) | [65.0%](/filings/0001823239-25-000034.md) | [(11.0%)](/filings/0001823239-26-000011.md) | [(90.9%)](/filings/0001823239-26-000011.md) | [(115.9%)](/filings/0001823239-26-000011.md) |
| Net margin | % | [22.8%](/filings/0001823239-24-000032.md) | [24.9%](/filings/0001823239-25-000034.md) | [(41.2%)](/filings/0001823239-26-000011.md) | [(55.9%)](/filings/0001823239-26-000011.md) | [(70.4%)](/filings/0001823239-26-000011.md) |
| Diluted EPS | $ per share | [1.56](/filings/0001823239-24-000032.md) | [1.67](/filings/0001823239-25-000034.md) | [(0.90)](/filings/0001823239-26-000011.md) | [(1.05)](/filings/0001823239-26-000011.md) | [(0.90)](/filings/0001823239-26-000011.md) |
| Free cash flow | $m | [354](/filings/0001823239-24-000032.md) | [519](/filings/0001823239-25-000034.md) | [60.7](/filings/0001823239-26-000011.md) | [(22.2)](/filings/0001823239-26-000011.md) | [(70.7)](/filings/0001823239-26-000011.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Gross profit: us-gaap:GrossProfit.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/mrvi/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [GTCR LLC](/funds/1576350.md) | 2026-06-30 | $125.7m | 20,150,005 |  | Unchanged |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $62.2m | 9,970,780 |  | Added +625,512 |
| [BRAIDWELL LP](/funds/1920938.md) | 2026-06-30 | $54.3m | 8,702,921 |  | Reduced −1,537,243 |
| [12 West Capital Management LP](/funds/1540531.md) | 2026-06-30 | $44.1m | 7,060,195 |  | Reduced −200,000 |
| [MILLENNIUM MANAGEMENT LLC](/funds/1273087.md) | 2026-06-30 | $40.6m | 6,508,220 |  | Added +4,858,730 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $33.0m | 5,283,665 |  | Reduced −166,037 |
| [Ophir Asset Management Pty Ltd](/funds/1844640.md) | 2026-06-30 | $30.1m | 4,826,698 |  | New +4,826,698 |
| [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $28.7m | 4,606,491 |  | Added +341,802 |
| [DEUTSCHE BANK AG\\](/funds/948046.md) | 2026-06-30 | $26.9m | 4,304,927 |  | Added +3,446,672 |
| [First Eagle Investment Management, LLC](/funds/1325447.md) | 2026-06-30 | $22.9m | 3,671,287 |  | Added +1,146,951 |

## Recent filings

[All 419 filings](/companies/mrvi/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-07 | 20:03 ET | [10-Q](/filings/0001823239-26-000059.md) | Quarterly report, period 2026-06-30 | 0001823239-26-000059 |
| 2026-08-06 | 20:05 ET | [8-K](/filings/0001823239-26-000056.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001823239-26-000056 |
| 2026-06-03 | 12:31 ET | [8-K](/filings/0001823239-26-000049.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.03 New direct financial obligation; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001823239-26-000049 |
| 2026-05-29 | 20:19 ET | [8-K](/filings/0001823239-26-000046.md) | 5.07 Shareholder vote results | 0001823239-26-000046 |
| 2026-05-08 | 20:30 ET | [10-Q](/filings/0001823239-26-000024.md) | Quarterly report, period 2026-03-31 | 0001823239-26-000024 |
| 2026-05-07 | 20:05 ET | [8-K](/filings/0001823239-26-000022.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001823239-26-000022 |
| 2026-04-24 | 20:29 ET | [DEF 14A](/filings/0001823239-26-000014.md) | Proxy statement, period 2026-05-26 | 0001823239-26-000014 |
| 2026-02-26 | 21:06 ET | [10-K](/filings/0001823239-26-000011.md) | Annual report, period 2025-12-31 | 0001823239-26-000011 |
| 2026-02-25 | 21:05 ET | [8-K](/filings/0001823239-26-000005.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001823239-26-000005 |
| 2025-11-07 | 21:21 ET | [10-Q](/filings/0001823239-25-000120.md) | Quarterly report, period 2025-09-30 | 0001823239-25-000120 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001823239-26-000011.md), filed Feb 26, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/1152e593-a266-48df-bed6-29f730dd256f)

## About the filer

- CIK: 1823239
- Tickers: MRVI
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: DE
- Filer category: Accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.